| Literature DB >> 33939213 |
In Young Yoo1, Jayho Han1, Sung Il Ha1, Young Jong Cha1, Shin Dong Pil1, Yeon-Joon Park1.
Abstract
BACKGROUND: Rapid and accurate microbial identification and antimicrobial susceptibility testing (AST) are essential for timely use of appropriate antimicrobial agents for bloodstream infection. To shorten the time for isolating colonies from the positive blood culture, various preparation methods for direct identification using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) system were developed. Here, we evaluated the SepsiPrep kit (ASTA Corp.) for direct identification of microorganisms and AST from positive blood cultures using MicroIDSys Elite MALDI-TOF MS system (ASTA Corp.) and VITEK-2 system (bioMérieux).Entities:
Keywords: AST; MALDI-TOF; SepsiPrep; direct identification; positive blood culture
Mesh:
Substances:
Year: 2021 PMID: 33939213 PMCID: PMC8183931 DOI: 10.1002/jcla.23744
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Proportion of correct identification rate among the 57 gram‐positive isolates and 67 gram‐negative isolates
| Microorganisms | No. of isolates | Correct identification | Microorganisms | No. of isolates | Correct identification |
|---|---|---|---|---|---|
| Gram‐positive isolates | Gram‐negative isolates | ||||
|
| 12 | 12 |
| 32 | 32 |
|
| 12 | 12 |
| 1 | 1 |
|
| 4 | 4 |
| 2 | 2 |
|
| 1 | 1 |
| 6 | 5 |
|
| 1 | 1 |
| 18 | 18 |
|
| 5 | 4 |
| 1 | 1 |
|
| 1 | 1 |
| 1 | 1 |
|
| 15 | 15 |
| 4 | 4 |
|
| 6 | 5 |
| 2 | 2 |
| Total | 57 | 55 (96.5%) | Total | 67 | 66 (98.5%) |
The accuracy of antimicrobial susceptibility test results obtained using the blood culture pellet versus conventional method VITEK‐2 system among 55 gram‐positive isolates
| Microorganisms | Antimicrobial agent | CA (No. (%)) | No. of strains with: | ||
|---|---|---|---|---|---|
| Very major error | Major error | Minor error | |||
|
( | Benzylpenicillin | 30 (100) | |||
| Oxacillin | 30 (100) | ||||
| Gentamicin | 27 (90.0) | 3 | |||
| Hebekacin | 30 (100) | ||||
| Ciprofloxacin | 29 (96.7) | 1 | |||
| Erythromycin | 30 (100) | ||||
| Telithromycin | 28 (93.3) | 2 | |||
| Clindamycin | 29 (96.7) | 1 | |||
| Linezolid | 30 (100) | ||||
| Teicoplanin | 26 (86.7) | 4 | |||
| Vancomycin | 30 (100) | ||||
| Tetracycline | 28 (93.3) | 2 | |||
| Tigecycline | 28 (93.3) | 2 | |||
| Nitrofurantoin | 30 (100) | ||||
| Fusidic acid | 30 (100) | ||||
| Rifampin | 30 (100) | ||||
| Trimethoprim/Sulfamethoxazole | 28 (93.3) | 2 | |||
| Total | 493 (96.7) | 4 | 1 | 12 | |
|
( | Benzylpenicillin | 18 (90.0) | 2 | ||
| Ampicillin | 20 (100) | ||||
| Ampicillin/Sulbactam | 20 (100) | ||||
| Gentamicin high level | 19 (95.5) | 1 | |||
| Streptomycin high level | 20 (100) | ||||
| Erythromycin | 17 (85.5) | 3 | |||
| Quinupristin/Dalfopristin | 19 (95.5) | 1 | |||
| Linezolid | 20 (100) | ||||
| Teicoplanin | 15 (75.5) | 5 | |||
| Vancomycin | 20 (100) | ||||
| Tigecycline | 19 (95.5) | 1 | |||
| Total | 207 (94.1) | 8 | 0 | 5 | |
|
( | Benzylpenicillin | 5 (100) | |||
| Ampicillin | 5 (100) | ||||
| Cefotaxime | 5 (100) | ||||
| Ceftriaxone | 5 (100) | ||||
| Levofloxacin | 5 (100) | ||||
| Moxifloxacin | 3 (75.0) | 1 | |||
| Erythromycin | 5 (100) | ||||
| Clindamycin | 5 (100) | ||||
| Linezolid | 5 (100) | ||||
| Vancomycin | 5 (100) | ||||
| Tetracycline | 5 (100) | ||||
| Tigecycline | 5 (100) | ||||
| Chloramphenicol | 5 (100) | ||||
| Total | 63 (98.4) | 0 | 0 | 1 | |
Abbreviation: CA, Categorical agreement.
The accuracy of antimicrobial susceptibility test results obtained using the blood culture pellet versus conventional method VITEK‐2 system among 66 gram‐negative isolates
| Microorganisms | Antimicrobial agent | CA (No. (%)) | No. of strains with: | ||
|---|---|---|---|---|---|
| Very major error | Major error | Minor error | |||
|
( | Ampicillin | 59 (100) | |||
| Amoxicillin/Clavulanate | 58 (98.3) | 1 | |||
| Piperacillin/Tazobactam | 57 (96.7) | 2 | |||
| Cefazolin | 59 (100) | ||||
| Cefoxitin | 58 (98.3) | 1 | |||
| Cefotaxime | 59 (100) | ||||
| Ceftazidime | 58 (98.3) | 1 | |||
| Cefepime | 59 (100) | ||||
| Aztreonam | 59 (100) | ||||
| Ertapenem | 59 (100) | ||||
| Imipenem | 59 (100) | ||||
| Amikacin | 59 (100) | ||||
| Gentamicin | 59 (100) | ||||
| Ciprofloxacin | 55 (93.3) | 4 | |||
| Tigecycline | 59 (100) | ||||
| Trimethoprim/Sulfamethoxazole | 58 (98.3) | 1 | |||
| Meropenem | 59 (100) | ||||
| Total | 993 (99.0) | 1 | 0 | 9 | |
|
Non‐fermentative Gram‐negative rods ( | Ampicillin/Sulbactam | 1 (100) | |||
| Ticarcillin/Clavulanate | 6 (85.7) | 1 | |||
| Piperacillin | 7 (100) | ||||
| Piperacillin/Tazobactam | 7 (100) | ||||
| Cefotaxime | 3 (100) | ||||
| Ceftazidime | 7 (100) | ||||
| Cefepime | 7 (100) | ||||
| Imipenem | 7 (100) | ||||
| Meropenem | 7 (100) | ||||
| Amikacin | 7 (100) | ||||
| Gentamicin | 7 (100) | ||||
| Ciprofloxacin | 7 (100) | ||||
| Minocycline | 2 (66.7) | 1 | |||
| Tigecycline | 2 (66.7) | 1 | |||
| Trimethoprim/Sulfamethoxazole | 3 (100) | ||||
| Aztreonam | 6 (100) | ||||
| Total | 86 (96.6) | 0 | 0 | 3 | |
Abbreviation: CA, Categorical agreement.
Discrepancies of antimicrobial susceptibility testing results between the direct method and the conventional method
| Microorganism | No. (%) of strains with: | ||
|---|---|---|---|
| Very major error ( | Major error ( | Minor error ( | |
|
| Tigecycline (2) | Telithromycin (1) | |
|
|
Gentamicin (1) Teicoplanin (1) | ||
|
| Trimethoprim/Sulfamethoxazole (2) | Clindamycin (1) |
Gentamicin (1) Ciprofloxacin (1) Telithromycin (1) Teicoplanin (3) Tetracycline (2) |
|
| Gentamicin (1) | ||
|
| Moxifloxacin (1) | ||
|
| Benzylpenicillin (2) |
Erythromycin (2) Tigecycline (1) | |
|
|
Gentamicin High‐Level (1) Teicoplanin (5) |
Erythromycin (1) Quinupristin/Dalfopristin (1) | |
|
| Trimethoprim/Sulfamethoxazole (1) |
Amoxicillin/Clavulanate (1) Piperacillin/Tazobactam (2) Ceftazidime (1) Ciprofloxacin (3) | |
|
|
Cefoxitin (1) Ciprofloxacin (1) | ||
|
| Ticarcillin/Clavulanate (1) | ||
|
|
Minocycline (1) Tigecycline (1) | ||